Buchumschlag

Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial

Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with poor prognosis. The current first-line treatment for advanced TNBC (aTNBC) is determined by the expression of programmed cell death-ligand 1 (PD-L1). In the ATRACTIB trial—a multicenter, single-arm, phase 2 stu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Gion, María (Verfasst von) , Blancas, Isabel (Verfasst von) , Cortez-Castedo, Patricia (Verfasst von) , Cortés-Salgado, Alfonso (Verfasst von) , Marmé, Frederik (Verfasst von) , Blanch, Salvador (Verfasst von) , Morales, Serafín (Verfasst von) , Díaz, Nieves (Verfasst von) , Calvo-Plaza, Isabel (Verfasst von) , Recalde, Sabela (Verfasst von) , Martínez-Bueno, Alejandro (Verfasst von) , Ruiz-Borrego, Manuel (Verfasst von) , Llabrés, Elisenda (Verfasst von) , Taberner, María Teresa (Verfasst von) , de Laurentiis, Michelino (Verfasst von) , García-Vicente, Silvia (Verfasst von) , Guerrero, José Antonio (Verfasst von) , Boix, Olga (Verfasst von) , Rodríguez-Morató, Jose (Verfasst von) , Sampayo-Cordero, Miguel (Verfasst von) , Antonarelli, Gabriele (Verfasst von) , Pérez-García, José Manuel (Verfasst von) , Cortés, Javier (Verfasst von) , Llombart-Cussac, Antonio (Verfasst von)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: August 2025
In: Nature medicine
Year: 2025, Jahrgang: 31, Heft: 8, Pages: 2746-2754
ISSN:1546-170X
DOI:10.1038/s41591-025-03734-3
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41591-025-03734-3
Verlag, kostenfrei, Volltext: http://www.nature.com/articles/s41591-025-03734-3
Volltext
Verfasserangaben:María Gion, Isabel Blancas, Patricia Cortez-Castedo, Alfonso Cortés-Salgado, Frederik Marmé, Salvador Blanch, Serafín Morales, Nieves Díaz, Isabel Calvo-Plaza, Sabela Recalde, Alejandro Martínez-Bueno, Manuel Ruiz-Borrego, Elisenda Llabrés, María Teresa Taberner, Michelino de Laurentiis, Silvia García-Vicente, José Antonio Guerrero, Olga Boix, Jose Rodríguez-Morató, Miguel Sampayo-Cordero, Gabriele Antonarelli, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac & on behalf of ATRACTIB Trial Investigators
Beschreibung
Zusammenfassung:Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with poor prognosis. The current first-line treatment for advanced TNBC (aTNBC) is determined by the expression of programmed cell death-ligand 1 (PD-L1). In the ATRACTIB trial—a multicenter, single-arm, phase 2 study—we evaluated the combination of atezolizumab, paclitaxel and bevacizumab as first-line treatment for patients with aTNBC, independently of PD-L1 status. The primary endpoint was investigator-assessed progression-free survival. One hundred female patients were enrolled, with most evaluable tumors being PD-L1-negative (97.6%). The primary endpoint was met, with a median progression-free survival of 11.0 months (95% confidence interval (CI): 9.0-13.4; P < 0.001). The objective response rate was 63.0% (95% CI: 52.8-72.4) and median overall survival was 27.4 months (95% CI: 23.4-37.4). No treatment-related deaths or new safety signals were observed. This combination demonstrated significant antitumor activity as first-line therapy for aTNBC patients and merits further investigation. ClinicalTrials.gov Identifier: NCT04408118.
Beschreibung:Online veröffentlicht: 4. Juni 2025
Gesehen am 30.09.2025
Beschreibung:Online Resource
ISSN:1546-170X
DOI:10.1038/s41591-025-03734-3

Ähnliche Einträge